Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

• Published in: Inflammatory bowel diseases Vol. 29; no. 1; pp. 27 - 41
• Main Authors: Lichtenstein, Gary R, Bressler, Brian, Francisconi, Carlos, Vermeire, Severine, Lawendy, Nervin, Salese, Leonardo, Sawyerr, Gosford, Shi, Hongjiong, Su, Chinyu, Judd, Donna T, Jones, Thomas, Loftus, Edward V
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 05.01.2023
• Subjects: Age groups; Clinical Research; Colitis, Ulcerative - epidemiology; Herpes Zoster - chemically induced; Herpes Zoster - epidemiology; Herpesvirus 3, Human; Humans; Inflammatory bowel disease; Janus Kinase Inhibitors - therapeutic use; Piperidines - adverse effects; Skin cancer; Skin Neoplasms; clinical response; ulcerative colitis; safety; age; tofacitinib

Abstract Background In patients with ulcerative colitis (UC), risks of infection and malignancies increase with age. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. This analysis assessed age as a risk factor for adverse events of special interest (AESI) in the...